Business Description
Operating from its headquarters in the UK, with a subsidiary in the USA, Deltex Medical manufactures and markets the TrueVue system which incorporates Oesophageal Doppler Monitoring (ODM) technology.
Deltex Medical’s TrueVue Monitor changes the way clinicians can care for patients having major surgery or when admitted to intensive care. ODM is the only technology to measure blood flow continuously in the central circulation; it is highly sensitive to changes in flow and measures them immediately and accurately. ODM is simple to use and enables clinicians to intervene quickly and safely, based on small changes in circulating blood volume and so avoid the dangers of reduced oxygen delivery – i.e. poor perfusion.
ODM guided intraoperative fluid management (IOFM) is a cornerstone of Enhanced Recovery; delivering better quality, more cost effective care. It means patients recover from their surgery faster, leave hospital sooner and in better health than they otherwise would do. Having established a substantial high quality evidence base supporting wide-scale use of its products on both clinical and economic grounds, Deltex Medical is working with leading hospitals around the world to introduce ODM-guided fluid management into routine use.
Directors
Natalie Wettler – CEO & CFO
Natalie commenced her Deltex Medical career in 2011, holding a number of senior roles in the Group’s finance department between 2011 and 2016. Natalie re-joined the Group in January 2020 and was promoted to Group CFO in 2021. In August 2024, Natalie took on the additional responsibilities of COO and was subsequently appointed as CEO in February 2025. She has a Bachelor of Science Degree in Cognitive Science from the University of Sheffield and qualified as a Chartered Accountant with Grant Thornton in the UK and continued her Grant Thornton career in New Zealand. Natalie’s experience in the medical sector also includes head of Finance for Peak Primary Limited in New Zealand in the Primary Healthcare sector.
Non-Executive Directors
Nigel Keen – Chairman
Nigel has been involved with Deltex Medical since 1988 and has been Chairman since 1996. He is also Chairman of MedAccess Trust, a charity established to support MedAccess Guarantee Limited, a UK-based social finance company with the pioneering mission to make global healthcare markets work for everyone. His career has encompassed venture capital, industry and banking. He has a degree in engineering from Cambridge University and is a Fellow of the Institute of Engineering and Technology. He has been involved in the formation and development of high technology businesses for more than thirty years. Nigel is Chairman of the Remuneration Committee.
Chris Jones
Chris Jones joined the Board in June 2015 and brings over 30 years of experience in Fortune 500 and VC funded healthcare companies in both the UK and the USA. He is Executive Chairman of: Mologic Ltd, Global Access Health Ltd, and non-executive Director of MediSieve Ltd, Causeway Therapeutics Ltd, Carbometrics Ltd and Health Enterprise East Ltd. Chris is a US national who came to the UK in 2008 to become CEO of GlySure. Prior to joining GlySure he was CEO of Tensys Medical developing and commercialising a novel continuous, non-invasive blood pressure monitor resulting in the sale of the company in 2008. Chris also spent nine years with Nellcor Inc, a division of Tyco Healthcare, most recently as VP of Marketing responsible for the $700M WW pulse oximetry and critical care businesses. He has a Bachelor of Science Degree in Molecular Biophysics and Biochemistry from Yale University.
Ben Carswell
Ben joined the Board in December 2023 and is Chairman of the Audit Committee. He has more than 15 years’ experience commercialising Software-as-a-Service (“SaaS”) platforms for start-ups and established businesses. He is currently Director of Platform Licensing at Kraken Technologies, which forms part of Octopus Energy Group. Ben was previously Chief Commercial Officer at DPR Limited and held senior commercial and finance positions at Fiserv Inc (EMEA) and MoPowered Group plc. He worked in structured finance for RBS (Global Banking Markets) after completing his MBA from Oxford University. Ben started his career working for PwC where he qualified as a Chartered Accountant, working in the UK and the Americas.
Board Committees
Audit Committee
The committee is chaired by Ben Carswell and is composed of the remaining non-executive board members. It assists the board in fulfilling its oversight responsibilities. The primary functions are: to monitor the integrity of the company’s financial statements and other information to shareholders, to monitor the integrity of the company’s systems of internal control (including risk management), to oversee the company’s relationship with its external auditors and to review the effectiveness of the audit process.
Remuneration Committee
This committee comprised of the Chair, Nigel Keen, and the remaining non-executive board members. The primary function of the committee is to determine the remuneration packages of the company’s executive directors and the award of company share options to the company’s employees, on behalf of the board.
Advisors
Principal Bankers
NatWest Commercial Banking
5 East Street
Chichester
West Sussex
PO19 1HH
Independent Auditors
Cooper Parry Group Limited
Sky View
Argosy Road
East Midlands Airport
Castle Donington
Derby
DE74 2SA
Registrars
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA
Share Information
Deltex Medical Group plc (“Deltex Medical” or the “Group”)
Investor Information – matched bargain facility
The following information is intended to act as a summary / guide as to how to trade Deltex Medical ordinary shares on the JP Jenkins’ share matching platform. For definitive information please contact JP Jenkins by telephone on: +44 (0) 20 7469 0937; or via email at info@jpjenkins.com.
Following cancellation of admission of the Group’s ordinary shares (“Shares”) to trading on AIM on 21 February, 2025, the Shares have been admitted onto the JP Jenkins share matching platform under the ticker: DEMG.
Investors wishing to trade in the Shares can do so through their stockbroker.
Trades will be conducted where JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK-regulated stockbroker.
The indicative pricing for the Shares – as well as the transaction history – is available on the JP Jenkins’ website at www.jpjenkins.com.
Please note that: (i) there will be fees payable to JP Jenkins when trading the Shares; and (ii) purchases of Shares are likely to incur Stamp duty Reserve tax (SDRT). For more information, please call JP Jenkins on +44 (0) 20 7469 0937 or by emailing them at: info@jpjenkins.com
Number of shares in issue
The Company’s issued share capital comprises 1,896,025,700 ordinary shares of 0.01p each. All of the shares are fully paid; no shares are held as treasury shares.
This information was last updated on 16 January 2025.